Brief: Regenxbio Announces Positive Data From Pivotal Dose Level Of Rgx-121 Demonstrating Long-Term Systemic Effect

Regenxbio

03/09/2024 13:33

Regenxbio Inc  RGNX.O :
    * REGENXBIO ANNOUNCES POSITIVE DATA FROM PIVOTAL DOSE LEVEL
OF
RGX-121 DEMONSTRATING LONG-TERM SYSTEMIC EFFECT
    * REGENXBIO INC - SUBMISSION OF A ROLLING BLA USING
ACCELERATED
APPROVAL PATHWAY ON TRACK FOR Q3 2024
    * REGENXBIO INC - 80% OF PATIENTS WHO RECEIVED PIVOTAL DOSE
DISCONTINUED INTRAVENOUS ENZYME REPLACEMENT THERAPY OR REMAINED
TREATMENT-NAÏVE
    * REGENXBIO INC - APPROVAL OF PLANNED BLA COULD RESULT IN
RECEIPT
OF A PRIORITY REVIEW VOUCHER IN 2025

Source text for Eikon:  ID:nPn2R5MjHa 
Further company coverage:  RGNX.O